Noble Financial Remains a Buy on Tonix Pharma (TNXP)

In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Tonix Pharma (TNXPResearch Report), with a price target of $6.50. The company’s shares closed yesterday at $0.46.

According to TipRanks, LeBoyer is an analyst with an average return of -1.9% and a 26.71% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as PDS Biotechnology, Ayala Pharmaceuticals, and Tonix Pharma.

Currently, the analyst consensus on Tonix Pharma is a Moderate Buy with an average price target of $6.50.

See Insiders’ Hot Stocks on TipRanks >>

Based on Tonix Pharma’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $23.14 million. In comparison, last year the company had a GAAP net loss of $23.55 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecules and biologics to treat psychiatric, pain and addiction conditions, to improve biodefense through potential medical counter-measures, to treat transplant rejection and to treat gastric and pancreatic cancers. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.

Read More on TNXP:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More